Consensus statements	Level	Grade
•HCC is a rare tumor in children. However, it is the second most common primary liver cancer after hepatoblastoma.	I
•Hepatitis B is the most common cause of HCC in older children in countries with a high prevalence of the infection; now reduced incidence as neonates being vaccinated.	I
•Etiologies like tyrosinemia type 1, PFIC 2, Glycogen storage disorders type 1 and IV are predisposed to development of HCC in children	I
•In India, majority of HCCs are discovered on explants with etiology of metabolic liver disease and not Hepatitis B	II-2
•Hepatoblastomas need to be differentiated from HCCs and occur in a younger age group: usually less than 2 years of age and in the absence of background cirrhosis.	I	Strong
•The best treatment option for HCC in children is curative resection.	I	Strong
•Systemic chemotherapy with cisplatin and doxorubicin (PLADO) with or without sorafenib improves survival in children with HCC either as a neoadjuvant before resection or in unresectable tumors.	II-2	Weak
•Role of sorafenib is not established in children.	II-3
•TACE may have a role in advanced HCC in children.	II-3	Weak
•There is no data on RFA for HCCs in children.	II-3
•Selection criteria for liver transplantation are individual based and transplant could be considered in children with no extra-hepatic tumor or gross vascular invasion on imaging, irrespective of the number or size of the lesions.	II-2	Weak

TACE, transarterial chemoembolization; HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; PFIC, progressive familial intrahepatic cholestasis.